Bürke Çırçırlı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bürke Çırçırlı has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Mutay Aslan
Department of Medical Biochemistry, Akdeniz University Faculty of Medicine, Antalya, Turkey
2 shared publications - Bora Dinc
Akdeniz University
1 shared publication - Ilker Onguc Aycan
Department of Anaesthesiology and Reanimation, Faculty of Medicine, Akdeniz University , Antalya 07000
1 shared publication - Mert Can Emre
Motor Vehicles Department, Sorgun Vocational School, Yozgat Bozok University, 66000 Yozgat, Türkiye
1 shared publication - Senem Ece Üner
Department of Gene and Cell Therapy, Faculty of Medicine Akdeniz University Antalya Turkey
1 shared publication - Tuğçe Çeker
Department of Medical Biochemistry, Akdeniz University Faculty of Medicine, Antalya, Turkey
1 shared publication
Latest Publications
CerS2 Overexpression Enhances Palmitoyl‐ CoA –Induced Cytotoxicity and Alters Ceramide Species Composition in Breast Cancer Cells
Sphingolipid metabolism, particularly the balance between pro‐apoptotic ceramide and pro‐survival sphingosine‐1‐phosphate (S1P), has been associated with breast cancer progression. The aim of the present study was to examine whether ceramide synthase 2 (CerS2) overexpression is associated with changes in increased palmitoyl‐CoA (PCA) based ceramide buildup and cell fate changes in MCF‐7 breast cancer cells, a hormone receptor–positive model. CERS2 plasmid transfected cells were treated with PCA and/or the CerS inhibitor, fumonisin B1 (FB1). Cell viability, the proliferation marker proliferating cell nuclear antigen (PCNA), apoptosis (TUNEL and cleaved caspase‐3), and sphingolipid profiles were evaluated. High‐dose PCA (100 μM) significantly reduced MTT signal and PCNA expression and increased apoptotic markers, with stronger effects in CerS2‐overexpressing cells. Across short‐ and longer‐term exposures, the response pattern was concentration‐ and time‐responsive but not uniformly monotonic. Lipidomic analysis revealed that PCA and CerS2 overexpression increased C16 ceramide and very‐long‐chain ceramides (C22–C24), respectively. FB1 decreased the level of ceramide, elevated S1P and partly counteracted PCA‐induced cytotoxicity. FB1 pre‐treatment which was applied sequentially restricted but did not eliminate apoptosis. These findings indicate that CerS2 overexpression reshapes the cellular response to substrate‐driven sphingolipid stress by altering acyl‐chain–specific ceramide composition and the balance between ceramide‐ and S1P‐associated signaling. Rather than reflecting isolated pathway effects, the results support a context‐dependent role for CerS2 in modulating apoptotic sensitivity in MCF‐7 breast cancer cells.
CerS2 Overexpression Enhances Palmitoyl‐ CoA –Induced Cytotoxicity and Alters Ceramide Species Composition in Breast Cancer Cells
Sphingolipid metabolism, particularly the balance between pro‐apoptotic ceramide and pro‐survival sphingosine‐1‐phosphate (S1P), has been associated with breast cancer progression. The aim of the present study was to examine whether ceramide synthase 2 (CerS2) overexpression is associated with changes in increased palmitoyl‐CoA (PCA) based ceramide buildup and cell fate changes in MCF‐7 breast cancer cells, a hormone receptor–positive model. CERS2 plasmid transfected cells were treated with PCA and/or the CerS inhibitor, fumonisin B1 (FB1). Cell viability, the proliferation marker proliferating cell nuclear antigen (PCNA), apoptosis (TUNEL and cleaved caspase‐3), and sphingolipid profiles were evaluated. High‐dose PCA (100 μM) significantly reduced MTT signal and PCNA expression and increased apoptotic markers, with stronger effects in CerS2‐overexpressing cells. Across short‐ and longer‐term exposures, the response pattern was concentration‐ and time‐responsive but not uniformly monotonic. Lipidomic analysis revealed that PCA and CerS2 overexpression increased C16 ceramide and very‐long‐chain ceramides (C22–C24), respectively. FB1 decreased the level of ceramide, elevated S1P and partly counteracted PCA‐induced cytotoxicity. FB1 pre‐treatment which was applied sequentially restricted but did not eliminate apoptosis. These findings indicate that CerS2 overexpression reshapes the cellular response to substrate‐driven sphingolipid stress by altering acyl‐chain–specific ceramide composition and the balance between ceramide‐ and S1P‐associated signaling. Rather than reflecting isolated pathway effects, the results support a context‐dependent role for CerS2 in modulating apoptotic sensitivity in MCF‐7 breast cancer cells.
- Open Access
- 30 December 2025
- Published by Özgür Yayınları
- p. 71-92
Biyomalzemelerle Sinyal Yolu Modülasyonu: Hücresel Mekanizmalardan Terapötik Uygulamalara
Hücresel sinyal yolları, çok hücreli organizmalarda homeostaz, büyüme ve farklılaşma gibi temel biyolojik süreçlerin biyokimyasal temelini oluşturur. Bu yolların düzensizliği ise kanser ve inflamatuvar hastalıklar dahil pek çok patolojinin gelişiminde anahtar rol oynar. Bu bölüm, biyomalzemelerin sinyal yollarını hedeflemedeki dönüştürücü potansiyelini ele almaktadır. Nanopartiküller, ekzomlar ve uyarıma duyarlı sistemler, terapötik ajanları koruyarak ve hastalıklı dokuya özgül bir şekilde yönlendirerek hem sistemik toksisiteyi azaltmakta hem de ilaç etkinliğini artırmaktadır. Biyomalzeme tasarımında, mekanotransdüksiyon, biyouyumluluk ve yüzey modifikasyonu gibi faktörler, hücre kader kararlarını yönlendiren kritik unsurlardır. Gelecek perspektifleri, Lab-on-Chip (LoC) sistemleri, sensör entegreli implantlar ve kişiselleştirilmiş 3D/4D biyo-baskı teknolojileri gibi akıllı platformlara odaklanmaktadır. Bu yenilikçi sistemler, yerel biyobelirteç konsantrasyonlarına yanıt veren geri bildirim kontrollü ilaç salımını mümkün kılar. Sinyal rehberliğinde biyomateryal mühendisliği, biyokimyasal bozukluklara karşı bireyselleştirilmiş, hassas ve etkin tedavi stratejilerinin geliştirilmesinde kritik bir rol oynamaktadır.
- 30 December 2025
- Published by Özgür Yayınları
- p. 71-92
Open AccessBiyomalzemelerle Sinyal Yolu Modülasyonu: Hücresel Mekanizmalardan Terapötik Uygulamalara
Hücresel sinyal yolları, çok hücreli organizmalarda homeostaz, büyüme ve farklılaşma gibi temel biyolojik süreçlerin biyokimyasal temelini oluşturur. Bu yolların düzensizliği ise kanser ve inflamatuvar hastalıklar dahil pek çok patolojinin gelişiminde anahtar rol oynar. Bu bölüm, biyomalzemelerin sinyal yollarını hedeflemedeki dönüştürücü potansiyelini ele almaktadır. Nanopartiküller, ekzomlar ve uyarıma duyarlı sistemler, terapötik ajanları koruyarak ve hastalıklı dokuya özgül bir şekilde yönlendirerek hem sistemik toksisiteyi azaltmakta hem de ilaç etkinliğini artırmaktadır. Biyomalzeme tasarımında, mekanotransdüksiyon, biyouyumluluk ve yüzey modifikasyonu gibi faktörler, hücre kader kararlarını yönlendiren kritik unsurlardır. Gelecek perspektifleri, Lab-on-Chip (LoC) sistemleri, sensör entegreli implantlar ve kişiselleştirilmiş 3D/4D biyo-baskı teknolojileri gibi akıllı platformlara odaklanmaktadır. Bu yenilikçi sistemler, yerel biyobelirteç konsantrasyonlarına yanıt veren geri bildirim kontrollü ilaç salımını mümkün kılar. Sinyal rehberliğinde biyomateryal mühendisliği, biyokimyasal bozukluklara karşı bireyselleştirilmiş, hassas ve etkin tedavi stratejilerinin geliştirilmesinde kritik bir rol oynamaktadır.
- Open Access
- 7 November 2023
- Published by Akdeniz University in Akdeniz Medical Journal
High Density Lipoprotein Subfraction Changes in End Stage Liver Failure
BACKGROUND: This work was designed to ascertain high-density lipoprotein (HDL) subfractions and HDL-related enzyme alterations in end stage liver failure (ESLF). METHODS: Twenty patients with ESLF and twenty control subjects (liver donors) were chosen for the study. Before the transplant, serum samples from each patient and control were evaluated. Continuous disc polyacrylamide gel electrophoresis was performed to determine HDL subfraction changes and ELISA was carried out to determine serum levels of lecithin–cholesterol acyltransferase (LCAT), apolipoprotein A-1 (ApoA-I) and cholesteryl ester transfer protein (CETP). RESULTS: Liver failure patients had significantly higher levels of triglycerides (TG) and very low-density lipoprotein (VLDL) compared to healthy donors. Additionally, these patients showed significant increases in levels of aspartate aminotransaminase (AST), alkaline phosphatase (ALP), alanine aminotransaminase (ALT), and blood urea nitrogen (BUN), while albumin was notably lower compared to controls. Even though HDL cholesterol concentrations were not considerably altered between the two groups, ESLF patients had a marked raise in the HDL-large subfraction and a significant decline in the HDL-small subfraction in contrast to controls. Moreover, liver failure patients had considerably lower serum ApoA1 levels compared to healthy controls, but there was no significant difference in LCAT and CETP levels between the two groups. CONCLUSION: HDL subfraction profile can distinguish between healthy donors and liver failure patients. The results also indicate that levels of ApoA-1, which performs a crucial function in HDL metabolism, are lower in ESLF. This decrease in HDL-small subfractions may be due to impaired anabolism resulting from hepatic failure.
- 7 November 2023
- Published by Akdeniz University in Akdeniz Medical Journal
Open AccessHigh Density Lipoprotein Subfraction Changes in End Stage Liver Failure
BACKGROUND: This work was designed to ascertain high-density lipoprotein (HDL) subfractions and HDL-related enzyme alterations in end stage liver failure (ESLF). METHODS: Twenty patients with ESLF and twenty control subjects (liver donors) were chosen for the study. Before the transplant, serum samples from each patient and control were evaluated. Continuous disc polyacrylamide gel electrophoresis was performed to determine HDL subfraction changes and ELISA was carried out to determine serum levels of lecithin–cholesterol acyltransferase (LCAT), apolipoprotein A-1 (ApoA-I) and cholesteryl ester transfer protein (CETP). RESULTS: Liver failure patients had significantly higher levels of triglycerides (TG) and very low-density lipoprotein (VLDL) compared to healthy donors. Additionally, these patients showed significant increases in levels of aspartate aminotransaminase (AST), alkaline phosphatase (ALP), alanine aminotransaminase (ALT), and blood urea nitrogen (BUN), while albumin was notably lower compared to controls. Even though HDL cholesterol concentrations were not considerably altered between the two groups, ESLF patients had a marked raise in the HDL-large subfraction and a significant decline in the HDL-small subfraction in contrast to controls. Moreover, liver failure patients had considerably lower serum ApoA1 levels compared to healthy controls, but there was no significant difference in LCAT and CETP levels between the two groups. CONCLUSION: HDL subfraction profile can distinguish between healthy donors and liver failure patients. The results also indicate that levels of ApoA-1, which performs a crucial function in HDL metabolism, are lower in ESLF. This decrease in HDL-small subfractions may be due to impaired anabolism resulting from hepatic failure.